Adverum Biotechnologies, Inc. — Revenue by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/0362f620-a377-4b20-ba71-8a05a4ad56c1/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2024 | $1.0M | 2024-01-01 – 2024-12-31 | evidence 0001628280-25-017767 |
| FY 2023 | $3.6M | 2023-01-01 – 2023-12-31 | evidence 0001628280-24-011648 |
| FY 2022 | $0 | 2022-01-01 – 2022-12-31 | evidence 0001628280-23-009899 |
| FY 2021 | $7.5M | 2021-01-01 – 2021-12-31 | evidence 0001628280-22-007698 |
| FY 2020 | $0 | 2020-01-01 – 2020-12-31 | evidence 0001628280-21-003623 |
| FY 2019 | $250.0k | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-010503 |
| FY 2018 | $1.6M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-006536 |
| FY 2017 | $1.8M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-006536 |
| FY 2015 | $2.3M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-014022 |
| FY 2014 | $572.0k | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-078923 |
| FY 2013 | $480.0k | 2013-01-01 – 2013-12-31 | evidence 0001193125-15-078923 |
| FY 2012 | $30.0k | 2012-01-01 – 2012-12-31 | evidence 0001193125-15-078923 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Adverum Biotechnologies, Inc. — all facts · Net Income · Operating Income